Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations

Area of Science:

• Infectious Diseases
• Vaccinology
• Epidemiology

Background:

• Pneumococcal infections pose a significant health risk, especially to individuals with underlying medical conditions.
• Pneumococcal polysaccharide vaccine (PPSV) is recommended for populations at increased risk of invasive pneumococcal disease.
• Assessing vaccine efficacy and duration of protection is crucial for public health strategies.

Purpose of the Study:

• To evaluate the efficacy of the pneumococcal polysaccharide vaccine in specific at-risk populations.
• To determine the duration of protective immunity conferred by the vaccine.
• To inform vaccination recommendations for target groups.

Main Methods:

• Indirect cohort analysis comparing vaccinated and unvaccinated individuals over 14 years of national surveillance.
• Inclusion of 2837 participants over 5 years old with pneumococcus isolated from blood or cerebrospinal fluid.
• Utilized pneumococcal isolates submitted to the Centers for Disease Control and Prevention from US hospital laboratories.

Main Results:

• Overall vaccine efficacy against vaccine serotypes was 57%.
• High efficacy observed in specific populations: diabetes (84%), coronary vascular disease (73%), congestive heart failure (69%), chronic pulmonary diseases (65%), and anatomic asplenia (77%).
• Efficacy remained strong over time, with 71% at 5-8 years and 80% at 9+ years post-vaccination; no decline was documented.

Conclusions:

• Pneumococcal polysaccharide vaccine demonstrates substantial efficacy in preventing invasive pneumococcal disease in recommended at-risk populations.
• The vaccine provides durable protection, with sustained efficacy for at least nine years.
• While intensified vaccination efforts are encouraged for specific groups, universal revaccination is not currently supported by the data.